Completed Studies

Past Achievements

  1. We are pioneers in the development of glycine transporter-I (GlyT-1) inhibitor and D-amino acid oxidase (DAAO) inhibitor for the treatment of schizophrenia, obsessive compulsive disorder, and dementia.
  2. We are the first group to show the efficacy and safety of GlyT-1 inhibitor in the treatment of major depressive disorder. We conducted a study which showed that sarcosine (a GlyT-1 inhibitor to increase glycine levels in synapse) was more efficacious than citalopram, a commonly used antidepressant which is a selective serotonin reuptake inhibitor (SSRI), in the treatment of patients with major depressive disorder (Biological Psychiatry, 2013). This is a brand-new mechanism of treatment for depression.